hydrogen has been researched along with Parkinson Disease in 19 studies
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.
dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1." | 2.78 | Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. ( Hattori, N; Hirayama, M; Nakahara, T; Ohta, S; Takanashi, M; Yoritaka, A, 2013) |
| " Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.35 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. ( Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Dănău, A | 1 |
| Dumitrescu, L | 1 |
| Lefter, A | 1 |
| Tulbă, D | 1 |
| Popescu, BO | 1 |
| Hasuike, Y | 1 |
| Endo, T | 1 |
| Koroyasu, M | 1 |
| Matsui, M | 1 |
| Mori, C | 1 |
| Yamadera, M | 1 |
| Fujimura, H | 1 |
| Sakoda, S | 1 |
| Kobayashi, Y | 2 |
| Imamura, R | 1 |
| Koyama, Y | 1 |
| Kondo, M | 1 |
| Kobayashi, H | 1 |
| Nonomura, N | 1 |
| Shimada, S | 1 |
| Hong, CT | 1 |
| Hu, CJ | 1 |
| Lin, HY | 1 |
| Wu, D | 1 |
| Yamamoto, H | 1 |
| Ichikawa, Y | 1 |
| Hirano, SI | 1 |
| Sato, B | 1 |
| Takefuji, Y | 1 |
| Satoh, F | 1 |
| Yoritaka, A | 4 |
| Hayashi, T | 1 |
| Saiki, S | 1 |
| Hattori, N | 4 |
| Ostojic, SM | 1 |
| Illes-Toth, E | 1 |
| Rempel, DL | 1 |
| Gross, ML | 1 |
| Ohtsuka, C | 2 |
| Maeda, T | 2 |
| Hirayama, M | 6 |
| Abe, T | 2 |
| Watanabe, H | 3 |
| Saiki, H | 2 |
| Oyama, G | 2 |
| Fukae, J | 2 |
| Shimo, Y | 2 |
| Hatano, T | 2 |
| Kawajiri, S | 2 |
| Okuma, Y | 2 |
| Machida, Y | 2 |
| Miwa, H | 2 |
| Suzuki, C | 2 |
| Kazama, A | 2 |
| Tomiyama, M | 2 |
| Kihara, T | 2 |
| Hirasawa, M | 2 |
| Shimura, H | 2 |
| Oda, E | 1 |
| Ito, M | 4 |
| Ohno, K | 3 |
| Suzuki, A | 1 |
| Hamaguchi, T | 1 |
| Mori, H | 1 |
| Takeda, Y | 1 |
| Baba, R | 1 |
| Watanabe, T | 1 |
| Kurokawa, K | 1 |
| Asakawa, S | 1 |
| Brenner, S | 1 |
| Tan, AH | 1 |
| Mahadeva, S | 1 |
| Thalha, AM | 1 |
| Gibson, PR | 1 |
| Kiew, CK | 1 |
| Yeat, CM | 1 |
| Ng, SW | 1 |
| Ang, SP | 1 |
| Chow, SK | 1 |
| Tan, CT | 1 |
| Yong, HS | 1 |
| Marras, C | 1 |
| Fox, SH | 1 |
| Lim, SY | 1 |
| McCarty, MF | 1 |
| Fu, Y | 1 |
| Fujita, Y | 1 |
| Ichihara, M | 1 |
| Masuda, A | 1 |
| Suzuki, Y | 1 |
| Maesawa, S | 1 |
| Kajita, Y | 1 |
| Ohsawa, I | 1 |
| Ohta, S | 2 |
| Fujita, K | 1 |
| Seike, T | 1 |
| Yutsudo, N | 1 |
| Ohno, M | 1 |
| Yamada, H | 1 |
| Yamaguchi, H | 1 |
| Sakumi, K | 1 |
| Yamakawa, Y | 1 |
| Kido, MA | 1 |
| Takaki, A | 1 |
| Katafuchi, T | 1 |
| Tanaka, Y | 1 |
| Nakabeppu, Y | 1 |
| Noda, M | 1 |
| Takanashi, M | 1 |
| Nakahara, T | 1 |
| Fukatsu, H | 1 |
| Katsuno, M | 1 |
| Sugiura, M | 1 |
| Hamada, K | 1 |
| Okada, Y | 1 |
| Ishigaki, T | 1 |
| Sobue, G | 1 |
| Sem-Jacobsen, CW | 1 |
| Styri, OB | 1 |
| Mohn, E | 1 |
2 reviews available for hydrogen and Parkinson Disease
| Article | Year |
|---|---|
Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease.
Topics: Blind Loop Syndrome; Dysbiosis; Gastrointestinal Microbiome; Humans; Hydrogen; Intestine, Small; Met | 2021 |
Molecular Hydrogen as a Novel Protective Agent against Pre-Symptomatic Diseases.
Topics: Alzheimer Disease; Animals; Asymptomatic Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Free | 2021 |
6 trials available for hydrogen and Parkinson Disease
| Article | Year |
|---|---|
Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Combined Modality Therapy; Double-Blind Method; Female | 2021 |
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study.
Topics: Aged; Animals; Antiparkinson Agents; Double-Blind Method; Humans; Hydrogen; Levodopa; Parkinson Dise | 2021 |
Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Hydrogen; Japan; Male; Middle Aged; | 2018 |
A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Hydrogen; Levodopa; Male; Middle Ag | 2016 |
Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Female; Humans; Hydrogen; Japan; Levodopa; Male; Mi | 2013 |
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.
Topics: Aspartic Acid; Brain Stem; Case-Control Studies; Cerebral Cortex; Creatine; Diagnosis, Differential; | 2004 |
11 other studies available for hydrogen and Parkinson Disease
| Article | Year |
|---|---|
Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bile Acids and Salts; Bilirubin; Blind Loop Syndrome; Breath Tests; Dysb | 2020 |
Renoprotective and neuroprotective effects of enteric hydrogen generation from Si-based agent.
Topics: Animals; Disease Models, Animal; Hydrogen; Kidney; Male; Mice; Neuroprotective Agents; Oxidative Str | 2020 |
Inadequate Production of H
Topics: Dysbiosis; Gastrointestinal Microbiome; Humans; Hydrogen; Parkinson Disease | 2018 |
Pulsed Hydrogen-Deuterium Exchange Illuminates the Aggregation Kinetics of α-Synuclein, the Causative Agent for Parkinson's Disease.
Topics: alpha-Synuclein; Amyloid; Deuterium Exchange Measurement; Humans; Hydrogen; Hydrophobic and Hydrophi | 2018 |
Quantification of hydrogen production by intestinal bacteria that are specifically dysregulated in Parkinson's disease.
Topics: Bacteria; Case-Control Studies; Feces; Gastrointestinal Microbiome; Humans; Hydrogen; Parkinson Dise | 2018 |
Parkinson's disease may be due to failure of melanin in the Substantia Nigra to produce molecular hydrogen from dissociation of water, to protect the brain from oxidative stress.
Topics: Animals; Antioxidants; Brain; Calorimetry; Humans; Hydrogen; Melanins; Oxidative Stress; Parkinson D | 2014 |
Small intestinal bacterial overgrowth in Parkinson's disease.
Topics: Aged; Bacterial Infections; Female; Humans; Hydrogen; Intestinal Diseases; Lactulose; Male; Middle A | 2014 |
Potential ghrelin-mediated benefits and risks of hydrogen water.
Topics: Animals; Antioxidants; Free Radical Scavengers; Gastric Mucosa; Ghrelin; Hydrogen; Mice; Parkinson D | 2015 |
Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Topics: Administration, Oral; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; | 2009 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; L | 2009 |
Measurements in man of focal intracerebral blood flow around depth-electrodes with hydrogen gas.
Topics: Adult; Cerebrovascular Circulation; Electrodes, Implanted; Humans; Hydrogen; Methods; Middle Aged; N | 1972 |